BioElectronics Corp (BIEL) Earnings

BioElectronics Corp. engages in the development of wearable, neuromodulation devices for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications. The company is headquartered in Frederick, Maryland. The company went IPO on 2004-04-12. The company develops wearable, neuromodulation devices to safely mitigate neurological diseases and enhance quality of life. Its flagship product, the ActiPatch Musculoskeletal Pain Therapy, is developed to relieve chronic pain. The Company’s pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. Its product line includes ActiPatch Musculoskeletal Pain Therapy, and RecoveryRx Post-operative and Chronic Wounds Therapy, which are sold by or on the order of medical professionals. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. The company is focused on international customers to expand its distributions and sales.